GlassScriptPhysician profile
Jason R Thonhoff
NPI 1871885459
$62,296.21
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $1,315 · 2021: $105 · 2022: $1,942 · 2023: $53K · 2024: $5,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $8,320 · Consulting Fee: $7,823 · Food and Beverage: $1,524 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,890.00 |
| Travel and Lodging | $8,320.29 |
| Consulting Fee | $7,823.00 |
| Food and Beverage | $1,523.69 |
| Education | $127.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $54,783.41 | 2021-2024 | Spinraza, Spinraza, Qalsody |
| Genentech USA, INC. | $5,241.00 | 2022-2023 | Evrysdi |
| Mitsubishi Tanabe Pharma Development America, INC. | $1,271.76 | 2020 | |
| Csl Behring | $169.62 | 2019-2022 | |
| Genentech, INC. | $143.44 | 2021-2023 | Evrysdi |
| Avanir Pharmaceuticals, INC. | $116.41 | 2019-2022 | |
| Amylyx Pharmaceuticals, INC. | $106.19 | 2023-2024 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $94.78 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $79.28 | 2023-2024 | Nuedexta |
| Lilly USA, LLC | $63.74 | 2024 | Amyvid |
| Tanabe Pharma America, INC. | $41.80 | 2020-2024 | |
| Argenx US, INC. | $28.81 | 2022 | |
| Ge Healthcare | $22.80 | 2019 | |
| Merz North America, INC. | $22.51 | 2019 | |
| Lundbeck LLC | $19.63 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $17.08 | 2020 | |
| Shire North American Group INC | $16.51 | 2019 | |
| Genzyme Corporation | $15.01 | 2019 | |
| Abbvie INC. | $15.00 | 2021 | |
| Grifols USA, LLC | $14.01 | 2019 | |
| Amgen INC. | $13.42 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Thonhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.